Perea MA, Rodríguez HR, Otero MF, Zarco RJ

Language: Spanish
References: 17
Page: 27-32
PDF size: 206.50 Kb.

Text Extraction

REFERENCES

1. Long SS. Principles and practice of pediatric infectious diseases 3rd ed. Philadelphia. Churchill Livingstone; 2008: 1144-1153.

2. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases 6th ed. Philadelphia. Churchill Livingstone; 2005: 1580-1585.

3. Litalien C, Jacz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children. A comparison with paracetamol. Pediatr Drugs 2001; 3: 817-818.

4. Lesko SM et al. Invasive group A streptococcal infection and nonsteroideal antiinflammatory drug use among children with primary varicella. Pediatrics 2001; 107: 1108-1115.

5. Behm-Lopez B, Salas-Herrera I. El papel de los anti-inflamatorios no esteroideos en la producción de fascitis necrotizante. Acta Med Costarricense 2002; 44: 5-9.

6. Zerr MD, Rusell EA, Duchin JS, Koutsky LA, Rubens CE. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999; 103(4): 783-790.

7. Mikaeloff Y, Kezouh A, Suissa S. Non steroideal anti-inflammatory drug use and the risk of severe skin and soft tissue complication in patients with varicella or zoster disease. Br J Clin Pharmacol 2007; 2: 204-209.

8. Rodriguez SR, Maldonado VM. Artritis. En: Salas AM, Peñaloza MJ. Síndromes pediátricos. 5ª. Ed. México: Masson Doyma, 2002: 511-523.

9. Gerber MA. Fiebre reumática. En: Behrman RE, Kliegman RM, Jenson HB. Nelson Tratado de Pediatría. 17ª. Ed. España: Elsevier Saunders. 2004: 874-879.

10. Miller ML, Cassidy JT. Artritis reumatoide juvenil. En: Behrman RE, Kliegman RM, Jenson HB. Nelson Tratado de Pediatría. 17ª. Ed. España: Elsevier Saunders. 2004: 799-805.

11. Munro JE, Murray KJ. Advances in paediatric rheumatology: beyond NSAIDs and joint replacement. J Pediatr Child Health 2004; 40: 161-169.

12. ACR Committee for Academic Pediatric Rheumatology. The future status of pediatric rheumatology in the United States: strategic planning for the year 2000. Arthritis and Rheum 2000; 43: 239-242.

13. Andersohn F, Suissa S, Garbe E. Cyclooxigenase inhibitors and cardiovascular risk. JAMA 2007; 297: 586-587.

14. Rodríguez HR, Carbajal RL, Reynés MJ, García PC, Barrios FR, Zarco RJ, Belmont ML, Flores DJ. Enfermedad de Kawasaki. Acta Pediatr Mex 2001; 22: 97-103.

15. Pallasch TJ, Falace DA, Taubert KA et al. Diagnosis, treatment and long-term management of Kawasaki disease: A statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics 2004; 114: 1708-1733.

16. Rodríguez HR, Carbajal RL, Reynés MJ, Barrios FR, Zarco RJ. Abordaje diagnóstico y terapéutico de la enfermedad de Kawasaki. Acta Pediatr Mex 2006; 27: 36-49.

17. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: A meta-analysis of 862 children. Pediatrics 2005; 27: 989-995.